Literature DB >> 1370257

A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity.

Z Reiter1, O N Ozes, L M Blatt, M W Taylor.   

Abstract

Previous in vitro and in vivo studies have shown a synergism between interferon (IFN) and 5-fluorouracil (5-FU) against different tumor cell lines. In the present study we report that the combination of IFN-alpha and 5-FU has a significant effect not only on the inhibition of tumor cell growth but also on the regulation of natural killer cell-mediated cytotoxicity (NK-CMC). The addition of 5-FU to effector cell population neither affects NK cell activity nor activation of NK cells by IFN or by interleukin (IL)-2. However, pretreatment of target cells with 5-FU increased their susceptibility to NK activity and abolished the protective effect induced by IFN against NK-CMC. This dual effect of IFN-alpha and 5-FU was found to be applicable to target cells of different origins including a cervical carcinoma cell line (ME-180), a hairy cell leukemia-like cell line (Eskol), a CML cell line (K-562) and a primary culture of AIDS-related Kaposi's sarcoma cells. Similar results were found with IL-2 treatment of Eskol cells but not other cells. Combination of IL-2 with 5-FU resulted in enhancement of the sensitivity of the cells to NK activity and abolished the protection against NK-CMC. Based on these results we propose that the combination of IFN-alpha and 5-FU not only has a direct growth inhibitory effect on tumor cells but also has a regulatory role on the immunological arm of the NK-CMC. Moreover, since the combination gave the same pattern of response in different tumor cells, both NK-sensitive and NK-resistant, this combination treatment may be a candidate for clinical trials in various types of tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370257     DOI: 10.1016/0090-1229(92)90029-n

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

Review 1.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

2.  Induction of lymphokine-activated killer activity in mice by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G V Dedoussis; N G Papadopoulos; O Tsolas; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 3.  Cytokine-based biotherapy of gastrointestinal tumors.

Authors:  J Buer; H Kirchner; A Schomburg; A Schüler; M Manns; E Lopez-Hänninen; S Duensing; H Poliwoda; J Atzpodien
Journal:  Clin Investig       Date:  1994-07

Review 4.  Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.

Authors:  C M van Herpen; R L Jansen; W H Kruit; K Hoekman; G Groenewegen; S Osanto; P H De Mulder
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.

Authors:  J Atzpodien; H Kirchner; H J Illiger; B Metzner; D Ukena; H Schott; P J Funke; M Gramatzki; S Jürgenson; T Wandert; T Patzelt; M Reitz
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

7.  Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.

Authors:  K Midoro; K Gotoh; T Houkan; K Yukishige; K Fujiwara; K Ootsu
Journal:  Jpn J Cancer Res       Date:  1997-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.